Top Markets
#1 Status Status +18.91%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +18.45%
#4 Wrapped NXM Wrapped NXM +15.13%
#5 Ontology Gas Ontology Gas +11.65%
#6 DMT-NAT DMT-NAT +8.98%
#7 Pons Pons +8.13%
#8 Provenance Blockchain Provenance Blockchain +7.18%
#9 Nesa Nesa +7.18%
#10 Janction Janction +7.01%
Coin of the day
Status Status
Settings
Language
ENGLISH
Currency
USD
Theme
Curanex Pharmaceuticals Inc Common Stock Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc Common Stock

CURX
Rank in Stocks #34063
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused... Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Share Price
$0.223
Last synced: 2026-08-14
Market Cap
$6.32M
Change (1 day)
1.64%
Change (1 year)
-
Country
US
Trade Curanex Pharmaceuticals Inc Common Stock (CURX)

Category

Healthcare
P/E ratio for Curanex Pharmaceuticals Inc Common Stock (CURX)
P/E ratio as of 2026 TTM: 0
According to Curanex Pharmaceuticals Inc Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Curanex Pharmaceuticals Inc Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.